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1. Introduction  
Parkinson’s disease (PD) is the most common neurodegenerative movement disorder affecting 
millions of predominantly elderly individuals worldwide. Originally described as “The 
Shaking Palsy” in 1817 by the British physician, James Parkinson, the disease is attended by a 
constellation of motoric deficits including bradykinesia (slowness in movements), postural 
instability, rigidity and tremor that ultimately result in near total immobility. Although 
pathological changes are distributed in the PD brain, the principal neuropathology that 
underlies the characteristic motor phenotype of PD patients is unequivocally the loss of 
midbrain dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc), which 
results in a severe depletion of striatal dopamine and thereby an impaired nigrostriatal system 
that otherwise allows an individual to execute proper, coordinated movements. This specific 
pattern of neurodegeneration in PD is often accompanied by the presence of eosinophilic 
intracytoplasmic inclusions known as Lewy bodies (LBs) in surviving neurons in the SN as 
well as in other affected brain regions such as the dorsal motor nucleus of the vagus, locus 
ceruleus (LC) and olfactory nuclei (Braak et al., 2003). In advanced stages of the disease, LB 
pathology can also be found in the limbic structures and neocortex (Braak et al., 2003). Non-
motor features arising from these extra-nigral neuronal lesions, including autonomic, sensory 
and cognitive dysfunctions, present additional sources of considerable consternation and 
disability for affected individuals (Olanow et al., 2008). Thus, although SN pathology is often 
regarded as the most important hallmark of PD, the disease is increasingly being recognized as 
a multi-system disorder affecting not only dopaminergic, but also noradrenergic, cholinergic 
and serotonergic systems (Alexander, 2004). 
Despite intensive research, the etiology of PD remains poorly understood and no current 
treatments can unequivocally slow or stop the degenerative process. Current therapies for 
PD are palliative at best and the mainstay is pharmacologic intervention via DA 
replacement (e.g. through L-DOPA administration). Major drawbacks with current 
therapies include the inevitable loss of effectiveness and increasing drug-induced side 
effects as the disease progresses. Invariably, the debilitating nature and morbidity of the 
disease present significant healthcare, socio-economic and emotional problems. As the 
world population rapidly ages, these problems undoubtedly would also increase. Notably, a 
recent study by Dorsey et al projected that the number of PD cases in Europe’s five most 
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and the world’s ten most populous countries would increase to 9 million in year 2030 
(Dorsey et al., 2007). This is definitely a worrying trend, and one that aptly emphasizes the 
urgency to develop more effective treatment modalities for the PD patient.  
In large part, the difficulty in identifying disease-modifying drugs for PD is due to: i) our 
current limited understanding of the molecular mechanism(s) that underlies the 
pathogenesis of PD (the illumination of which would allow the identification and 
therapeutic exploitation of key molecules involved in the pathogenic process), and ii) the 
lack of a truly representative mammalian model of PD that recapitulates accurately the 
progressive process as well as the nature and distribution of the human pathology. 
However, during the last decade or so, the identification and functional characterization of 
several genes whose mutations are causative of rare familial forms of PD have provided 
tremendous insights into the molecular events underlying neurodegeneration in PD. 
Alongside, several genetic models of PD have also been generated that replicate the disease 
phenotype to varying degrees of success. Collectively, these studies implicate aberrant 
mitochondrial and protein homeostasis as key contributors to the development of PD, with 
oxidative stress likely acting an important nexus between the two pathogenic events. 
2. Parkin and Parkinson’s disease  
Mutations in α-synuclein, parkin, DJ-1, PINK1, and LRRK2 are currently recognized to be 
unequivocally linked to familial parkinsonism (Table 1). Whereas α-synuclein and LRRK2 
mutations are causative of dominant parkinsonism, mutations in parkin, DJ-1, PINK1 are 
associated with recessive parkinsonism (Thomas and Beal, 2007). 
 
Locus Chromosome Gene Inheritance Function
  
PARK1 & 4 4q21-23 
α-synuclein 
(SNCA)
Dominant 
Unclear (presynaptic 
protein)
PARK2 6q25.2-27 Parkin (PRKN) Recessive Ubiquitin ligase 
PARK3 2p13 Unknown Dominant -
PARK5 4p14 UCHL1 Dominant Ubiquitin hydrolase 
PARK6 1p35-36 PINK1 Recessive 
Putative 
serine/threonine kinase 
PARK7 1p36 DJ-1 Recessive Redox sensor 
PARK8 12p11.2-q13.1 LRRK2/dardarin Dominant 
Putative 
serine/threonine kinase 
PARK9 1p36 ATP13A2 Recessive 
Lysosomal P-type 
ATPase
PARK10 1p32 Unknown Unknown -
PARK11 2q37.1 Unknown Dominant -
PARK12 Xq21-q25 Unknown Unknown -
PARK13 2p12 Omi/HtrA2 Dominant 
Mitochondrial serine 
protease
PARK14 22q13.1 PLA2G6 Recessive Phosopholipase 
PARK15 22q12-q13 FBXO7 Recessive 
Component of SCF E3 
complex
PARK16 1q32 Unknown Unknown -
Table 1. PD-linked genes 
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Apart from these, mutations in UCHL1, Omi/HtrA2 and ATP13A2 have also been suggested 
to cause parkinsonism, but their relevance to PD is currently unclear because the purported 
disease-causing mutation is either extremely rare in occurrence (e.g. UCHL1 I93M) (Healy et 
al., 2004) or present in control population at similar frequencies (e.g. Omi/HtrA2 G399S) 
(Simon-Sanchez and Singleton, 2008) or otherwise results in a clinical phenotype that is 
rather divergent from classical PD (e.g. ATP13A2-linked parkinsonism that is characterized 
by mild parkinsonism and prominent cognitive defects) (Ramirez et al., 2006). More 
recently, two other genes, PLA2G6 encoding a phospholipase and FBXO7 encoding a 
component of the Skp-Cullin-Fbox (SCF) ubiquitin ligase complex, have also been identified 
to be associated with recessive parkinsonism (Di Fonzo et al., 2009; Paisan-Ruiz et al., 2009). 
The function of these various disease-associated genes, especially the unequivocal ones, has 
been extensively characterized. Interestingly, it turned out that these seemingly functionally 
disparate PD-linked proteins that have no clear relationship with each other at first glance 
may all influence either protein or mitochondrial homeostasis, with some, like parkin, being 
directly involved in both. Accordingly, in the absence of functional parkin, aberrations in 
both protein and mitochondrial quality control (QC) would ensue that may eventually 
trigger the demise of susceptible neurons. Indeed, the pivotal role parkin plays in 
maintaining DA neuronal survival is underscored by our current recognition that parkin 
dysfunction represents not only a predominant cause of familial parkinsonism but also a 
formal risk factor for the more common, sporadic form of PD. Here, we shall discuss the role 
of parkin in PD and why a better understanding of parkin function can help elucidate 
potential therapeutic strategies for the disease. 
2.1 Parkin mutations and parkinsonism  
Mutations in parkin were originally identified in Japan more than a decade ago to be 
causative of autosomal recessive juvenile parkinsonism (ARJP) (Kitada et al., 1998). 
Following this discovery, several ethnically diverse individuals with early-onset PD (age 
< 45 years) in other parts of the world were also found to carry parkin mutations, which 
occur at a frequency of about 10-20% and 50% in sporadic and familial early-onset cases 
respectively (Lucking et al., 2000; Mata et al., 2004; Periquet et al., 2003). Clinically, 
parkin-associated parkinsonism is often quite indistinguishable from idiopathic PD, with 
bradykinesia, rigidity and rest tremor being variably combined in both disorders. 
However, parkin-related patients tend to exhibit slower disease progression and better 
response to L-DOPA (and also a higher tendency to develop L-DOPA-induced dyskinesia) 
than those with parkinsonism of different etiologies. Additionally, other less typical 
features common to parkin cases include prominent dystonia, presence of hyperreflexia 
and more symmetrical presentation of symptoms, although none of these features are 
sufficiently specific to be diagnostic of parkin mutations. Limited post-mortem studies of 
known parkin cases conducted to date demonstrated neuronal loss predominantly in the 
SN and LC regions of the brain that is accompanied by gliosis. Importantly, the majority 
of parkin-related cases are devoid of classic LBs (Hayashi et al., 2000; Mori et al., 1998; 
Pramstaller et al., 2005), suggesting that parkin-associated parkinsonism is pathologically 
distinct from idiopathic PD, and as such may represent a phenocopy of the latter. 
However, this is debatable as LBs are found in at least two cases of parkin-related PD 
(Farrer et al., 2001; Pramstaller et al., 2005). An attractive corollary to this is that functional 
parkin may facilitate LB formation, which we favor as a working hypothesis (see section 
2.2).  
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Structurally, the 465 amino acid-containing human parkin protein is comprised of a 
ubiquitin-like (UBL) domain at its N-terminus, a RING1-IBR-RING2 domain at its C-
terminus and a unique middle segment that links the two domains (Fig. 1). Similar to other 
RING finger-containing proteins, parkin functions as an E3 ubiquitin ligase associated with 
the ubiquitin-proteasome system (UPS). To date, more than 100 different parkin mutations 
have been described with over 50 of these being missense/nonsense substitutions (Fig. 1). 
Although most of the missense mutations occur within the RING1-IBR-RING2 catalytic 
moiety, many of them are also found along the length of the protein outside this region. 
Further, exonic mutations are also frequently observed with deletion of exon 3 and/or 4 
being the most common (Hedrich et al., 2004). 
 
 
Fig. 1. Schematic depiction of parkin structure and associated disease-linked mutations 
including missense/nonsense substitutions, insertions, microdeletion as well as exonic 
multiplications and deletions. 
Curiously, despite the heterogeneity, there is no discernable difference in the clinical 
manifestations among PD patients carrying different parkin mutations. This suggests that 
substitutions of amino acids resulting from missense mutations are as detrimental to parkin 
function as are truncation and deletion mutations. Another curious, albeit controversial 
feature of parkin-related cases is that a single allelic hit might be sufficient to cause disease, 
which contradicts the widely accepted notion that parkin mutations transmit in a classical 
autosomal recessive manner (Klein et al., 2007). Supporting this, Hilker and colleagues 
demonstrated via positron emission tomography that asymptomatic carriers of a single 
parkin mutation exhibit significantly reduced fluorodopa uptake in the striatal regions 
compared to control subjects, suggesting preclinical dopaminergic dysfunction (Hilker et al., 
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2001). In concordance with this, a subsequent transcranial sonography-based study revealed 
SN hyperechogenicity in 5 out of 7 asymptomatic carriers of parkin mutations (Walter et al., 
2004). Moreover, fMRI analysis of heterozygous parkin carriers demonstrated 
reorganization of striatocortical motor loops that possibly reflect a compensatory effort to 
overcome latent nigrostriatal dysfunction (Buhmann et al., 2005). Notwithstanding these 
evidences, the pathogenicity of single heterozygous parkin mutation is a subject of ongoing 
debate. An outstanding issue is whether heterozygous parkin mutations may have arisen 
incidentally. Several studies have sought to address this, but the findings have thus far been 
inconsistent, i.e. heterozygosity for parkin mutations was reported to be similar between 
patients and controls in some studies (Kay et al., 2007; Lincoln et al., 2003) but also found to 
be unique to PD cases in others (Clark et al., 2006b). Another issue is how mutations 
occurring on a recessive gene can contribute to disease pathogenesis. Given the 
neuroprotective role of parkin function (discussed in later section), one could envisage that 
parkin haploinsufficiency could increase the risk of heterozygous parkin mutation carriers 
for PD. Supporting this, a promoter variant of parkin associated with a lower expression of 
parkin was found to occur more commonly in PD cases than in controls (West et al., 2002). 
Alternatively, emerging evidence suggest that certain parkin mutations may also contribute 
to neurotoxicity directly. The role of single heterozygous parkin mutations thus remains 
unresolved. 
Notwithstanding the controversy surrounding the role of heterozygous parkin mutations, 
how parkin mutations disrupt the function of the protein was a topic of intense research. 
Intuitively, one would posit that disease-associated mutations of parkin result in the loss of 
its enzymatic activity. Although this is true for mutations that occur on parkin’s RING2 
domain, several groups including ours have demonstrated that the majority of parkin 
missense mutants outside its RING2 domain retain their catalytic competency (Chung et al., 
2001; Hampe et al., 2006; Matsuda et al., 2006; Sriram et al., 2005; Wang et al., 2005). Instead, 
misfolding of parkin triggered by these mutations appears to be the major mechanism 
underlying parkin inactivation. Notably, missense parkin mutations frequently alter the 
protein solubility and concomitantly promote its aggregation into inclusion bodies (Ardley 
et al., 2003; Cookson et al., 2003; Gu et al., 2003; Hampe et al., 2006; Muqit et al., 2004; Sriram 
et al., 2005; Wang et al., 2005b). Amongst the aggregation-producing parkin mutations is the 
R275W substitution, which frequently occurs in the heterozygous state. Alternatively, some 
mutations of parkin compromise its function by destabilizing the protein and accelerating 
its degradation via the proteasome (Schlehe et al., 2008).    
2.2 Parkin-mediated ubiquitination and protein homeostasis   
As mentioned earlier, parkin functions as an E3 ligase associated with the UPS, a major 
proteolytic machinery that normally identifies and degrades unwanted intracellular 
proteins. In this system, proteins that are destined for proteasome-mediated degradation are 
added a chain of ubiquitin via a reaction cascade that involves the ubiquitin-activating (E1), 
-conjugating (E2) and -ligating (E3) enzymes. Through the sequential and repetitive actions 
of these enzymes, successive isopeptide linkages are formed between the C-terminal glycine 
carboxyl group (G76) of the ubiquitin moiety being added and the ε-amino group of a free 
lysine (most commonly K48) on the ubiquitin that is attached to the protein. The (G76-K48) 
polyubiquitinated substrate is then recognized by the 26S proteasome as a target for 
degradation. It is important to highlight that the ubiquitin sequence contains seven lysine 
residues (at positions 6, 11, 27, 29, 33, 48 and 63) and that polyubiquitin chain assembly can 
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occur at any of these lysine residues (Peng et al., 2003). In addition, proteins can also be 
monoubiquitinated. Notably, both K63-linked polyubiquitination and monoubiquitination 
of proteins are not typically associated with proteasome-mediated ubiquitination. 
Shortly after the discovery of parkin as a PD-linked gene, three independent groups 
demonstrated that parkin-mediated ubiquitination is linked to protein degradation and that 
disease-associated parkin mutations compromise its role as an E3 enzyme (Imai et al., 2000; 
Shimura et al., 2000; Zhang et al., 2000). A logical and popular hypothesis that ensued is that 
loss of parkin function could lead to a toxic accumulation of one or several of its substrates, 
thereby leading to neurodegeneration. This had fuelled intense effort by many laboratories 
around the world to identify the culprit substrate(s) involved. To date, no less than 25 substrates 
(or putative substrates) of parkin has been reported since the identification of CDCrel1 as the 
first putative substrate for the ubiquitin ligase (Zhang et al., 2000) (Table 2). However, none of 
the parkin substrates identified thus far is exclusively expressed in DA neurons, which raises 
the question on why DA neurons in familial parkinsonism cases linked to parkin mutations are 
selectively vulnerable to deficient parkin function. Further, few from the laundry list fulfil an 
important criterion expected of an “authentic” parkin substrate: accumulation in the brains of 
ARJP patients and parkin-deficient models (Table 2). Although the pace of substrate 
identification has slowed down considerably in recent years, new parkin substrates continue to 
emerge periodically. Amongst the most recently isolated parkin substrates is the zinc finger-
containing protein called PARIS (ZNF746) (Shin et al., 2011), a major transcriptional repressor of 
PGC-1α expression, which in turn regulates the transcription of many genes involved in cellular 
metabolism. Importantly, unlike most previously identified parkin substrates, PARIS 
accumulates in post-mortem brain tissues derived from ARJP and sporadic PD patients, as well 
as in the ventral midbrain region of mice that is conditionally ablated of parkin expression (Shin 
et al., 2011). Moreover, stereotactic injection of viral vector encoding PARIS into the SN of mice 
results in a selective loss of TH-positive DA neurons that can be rescued by either parkin or 
PGC-1α co-expression (Shin et al., 2011). Together, these results suggest that PARIS is an 
“authentic” parkin substrate and that its upregulation may underlie neurodegeneration due to 
parkin inactivation. Notwithstanding this and the fact that a few other substrates have similarly 
been reported to fulfil the criterion of a parkin substrate (Table 2), what constitutes an 
“authentic” substrate for parkin is really debatable, as discussed below. 
Although protein ubiquitination is classically associated with proteasome-mediated 
degradation, the existence of non-classic ubiquitin modifications such as K63-linked 
polyubiquitination would caution against the fixation on the traditional view that substrates of 
a ubiquitin ligase must exhibit an accelerated, proteasome-dependent turnover in the presence 
of the enzyme. This is particularly relevant to parkin, which we and others have demonstrated 
to be a multifunctional enzyme capable of mediating alternative ubiquitin topologies such as 
monoubiquitination and K63-linked polyubiquitination - modifications that are typically 
uncoupled from the proteasome and often considered as “non-proteolytic” (Doss-Pepe et al., 
2005; Hampe et al., 2006; Lim et al., 2005; Matsuda et al., 2006) (Fig. 2). Our results would 
argue that the catalytic function of parkin is not limited to targeting substrate for degradation 
by the proteasome. Thus, the lack of accumulation of an identified parkin substrate in the 
brains of ARJP patients and parkin-deficient models does not necessarily mean that it is less 
than an “authentic” substrate. For example, we have previously reported that parkin-mediated 
polyubiquitination of synphilin-1 (an interactor of α-synuclein) normally occurs via K63-linked 
chains, which does not appear to affect its steady-state turnover (Lim et al., 2005). Not 
surprisingly, the level of synphilin-1 is neither appreciably altered in ARJP brains nor in brain 
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tissues derived from parkin null mice (Ko et al., 2005). A corollary to this is that proteasome-
independent pathways may also be relevant to parkin-related neurodegeneration.   
 
 
Substrates 
Ub Type  Elevated in  Reference 
  KO mice ARJP Brain PD brain  
CDCrel-1 - Yes/No Yes/No - (Ko et al., 2005) 
CDCrel-2a - - Yes - (Choi et al., 2003) 
Synaptotagmin 
XI 
- Yes/No - - (Periquet et al., 2005) 
Synphilin-1 K63 No No  
(Chung et al., 2001; Ko et 
al., 2005; Lim et al., 2005) 
P38/AIMP2 
Multiple
Mono 
Yes Yes Yes 
(Corti et al., 2003; Hampe et 
al., 2006; Ko et al., 2005; 
Periquet et al., 2005) 
FBP1 - Yes Yes Yes (Ko et al., 2006) 
PARIS (ZNF746) K48 Yes Yes Yes (Shin et al., 2011) 
Cyclin E - No Yes/No Yes 
(Ko et al., 2005; Staropoli et 
al., 2003) 
PDCP2-1 - - Yes Yes (Fukae et al., 2009) 
Pael-R - No Yes/No - (Ko et al., 2005) 
α/β tubulin - Yes/No No - (Ko et al., 2005; Ren et al., 
2003) 
Hsp70 
Multiple
Mono 
No No Yes (Moore et al., 2008) 
PICK1 Mono No - - (Joch et al., 2007) 
VDAC1 
K27, 
Mono 
Yes - - 
(Geisler et al., 2010; 
Narendra et al.; Periquet et 
al., 2005) 
Ataxin-2 - Yes - - (Huynh et al., 2007) 
O-glycosylated 
α-synuclein - - Yes - (Shimura et al., 2001) 
RanBP2 - - - - (Um et al., 2006) 
Lim Kinase 1 - - - - (Lim et al., 2007) 
Eps15 Mono - - - (Fallon et al., 2006) 
DJ-1 L166P K63 - - - (Olzmann et al., 2007) 
Bcl-2 Mono - - - (Chen et al., 2010) 
Drp1 K48 - - - (Wang et al., 2011) 
Mitofusin - - - - 
(Poole et al., 2010; Ziviani et 
al., 2010) 
Dopamine 
Transporter 
- - - - (Jiang et al., 2004) 
Phospholipase 
Cγ1 - Yes - - (Dehvari et al., 2009) 
Ataxin3 polyQ79 - - - - (Tsai et al., 2003) 
Table 2. List of parkin substrates/putative substrates 
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By virtue of its apparent dissociation from the proteasome, we have originally proposed that 
parkin-mediated K63-linked ubiquitination may be involved in cargo diversion during 
proteasomal stress and accordingly, in the biogenesis of inclusion bodies associated with 
neurodegenerative diseases (Lim et al., 2006). Our proposal is consistent with the concept of 
aggresomes, which are juxtanuclear inclusion bodies formed in the presence of proteasomal 
stress and that have been suggested to act as staging grounds for the disposal of protein 
aggregates via the autophagic route (Kopito, 2000). Supporting our hypothesis, we found 
that parkin-mediated K63 polyubiquitination of synphilin-1 promotes its aggregation into 
aggresome-like inclusion bodies (Lim et al., 2005). Corroborating our findings, Olzmann et 
al demonstrated that parkin-mediated K63 polyubiquitination of misfolded DJ-1 couples the 
protein to the dynein motor complex via the histone deacetylase 6 (HDAC6) adaptor, 
thereby promoting its sequestration into aggresomes (Olzmann et al., 2007). Importantly, 
our recent work identified K63-linked polyubiquitin as a novel cargo selection signal for 
macroautophagy-mediated clearance of aggresomes (Tan et al., 2008a; Tan et al., 2008b). By 
being capable of mediating both proteasome-associated K48-polyubiquitination and 
macroautophagy-associated K63-linked polyubiquitination, parkin may potentially act as an 
important triage between the two major cellular degradation systems. This multi-
functionality of parkin may in part help explain its apparent broad neuroprotective 
properties, as the flexibility of ubiquitin linkage usage presumably would allow the enzyme 
to adapt rapidly to changes in cellular environment. 
2.3 Parkin-mediated ubiquitination and mitochondrial homeostasis   
One of the first hints that parkin may play a role in mitochondrial homeostasis aside from its 
role as a regulator of protein turnover came from a study in fruit flies. Greene and 
colleagues analyzed adult Drosophila parkin null mutant and observed that the most 
prominent pathology is not in the brain but in the flight musculature of these mutant flies, 
which is plagued by muscle degeneration and pronounced mitochondrial lesions (Greene et 
al., 2003). Interestingly, PINK1 null flies were subsequently found to phenocopy their parkin-
deficient counterparts and importantly, parkin over expression in PINK1-/- flies is able to 
rescue all the mutant phenotypes tested, although the reverse, does not happen (Clark et al., 
2006a; Park et al., 2006), suggesting that parkin acts in the same pathway but downstream of 
PINK1. We now know from several follow-up studies in flies and other model systems that 
the parkin/PINK1 pathway is a key regulator of mitochondrial dynamics, although it is 
currently controversial whether the pathway promotes mitochondrial fission or fusion [For 
a recent review, see (Burbulla et al., 2010)].  
In an exciting development, Narendra and colleagues from Youle laboratory have recently 
demonstrated that parkin plays an essential role in removing damaged mitochondria from 
the cell via a specialized form of autophagy known as mitophagy (Narendra et al., 2008). 
This has fuelled widespread interest amongst many researchers directed at elucidating the 
mechanism underlying parkin-mediated mitophagy, which is reminiscent of the initial 
excitement shared by many to uncover novel parkin substrates. A model (Fig. 2) that has 
emerged from a flurry of follow-up studies proposed that a key initial event that occurs 
upon mitochondrial depolarization is the selective accumulation of PINK1 in the outer 
membrane of the damaged organelle (presumably after its segregation by fission). Notably, 
PINK1 accumulation in healthy mitochondria is prevented by a proteolytic event that 
rapidly cleaves the protein (Narendra et al., 2010; Vives-Bauza et al., 2010). Upon 
recruitment to depolarized mitochondria by PINK1, parkin then becomes activated 
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(Matsuda et al., 2010) and promotes the ubiquitination and subsequent p97 AAA-ATPase-
regulated degradation of mitofusins (Poole et al., 2010; Ziviani et al., 2010), the elimination 
of which will prevent unintended fusion events involving damaged mitochondria and 
thereby their re-entry into undamaged mitochondrial network from occurring (Tanaka et al., 
2010). The event is then followed by the induction of mitophagy, which is also parkin-
dependent. Parkin-mediated K63 ubiquitination is apparently important here, as 
mitochondrial substrates that are modified by K63 polyubiquitin can presumably help in the 
recruitment of autophagy receptors such as HDAC6 and p62 to the damaged organelle. 
Notably, both HDAC6 and p62 are ubiquitin-binding proteins that preferentially recognize 
K63 ubiquitin chains (Lim and Lim, 2010; Olzmann et al., 2007; Tan et al., 2008a). The end 
result is the formation of “mito-aggresomes” and their subsequent clearance by lysosomes. 
The whole process thus resembles the formation and autophagic clearance of aggresomes. 
 
 
Fig. 2. Role of parkin in protein and mitochondrial QC. (Left) Parkin is a unique E3 enzyme 
capable of mediating various types of ubiquitin modification on its substrates that would 
result in different outcomes. (Right) A model of parkin/PINK1-mediated mitophagy.  
Despite the logic and experimental support for the events surrounding parkin-mediated 
mitophagy as described above, the model is not without controversy. Because the majority 
of studies related to parkin-mediated mitophagy were carried out in cells grown in glucose-
containing medium, a potential confounding factor is that these cells generate most of their 
ATP via glycolysis from glucose present in the medium, and not via oxidative 
phosphorylation. Notably, mitophagy is blocked in yeast that are made obligatorily 
dependent on mitochondrial metabolism, even under severe starvation conditions (Kanki 
and Klionsky, 2008). According to a recent study by Van Laar and colleagues, parkin-
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mediated mitophagy does not seem to take place appreciably in primary neurons treated 
with mitochondrial uncouplers such as CCCP (Van Laar et al., 2011). Unlike other cell types, 
neurons are strictly dependent on mitochondrial respiration. In HeLa cells (grown in 
glucose medium) where parkin-mediated mitophagy was originally observed, the 
phenomenon is similarly attenuated when these cells were forced into dependence on 
mitochondrial respiration (i.e. cultured in glucose-free medium) (Van Laar et al., 2011). 
Thus, parkin-mediated mitophagy appears to be dependent on the bioenergetic status of the 
cell. Presumably, additional mechanisms are involved in the regulation of mitophagy in 
neurons and other cell types that derive their energy from oxidative phosphorylation.  
Notwithstanding this, it is important to highlight that at least two groups have found that 
parkin accumulation on mitochondria does occur in primary neurons treated with CCCP 
(Narendra et al., 2008; Vives-Bauza et al., 2010). The reason for this discrepancy is presently 
unclear, but the conundrum obviously needs to be resolved as whether parkin-mediated 
mitophagy takes place appreciably in neurons has significant implications for its role in PD 
pathogenesis. 
Interestingly, parkin is also involved in mitochondrial biogenesis. Kuroda and colleagues 
previously demonstrated that parkin over-expression enhances the transcription and 
replication of mitochondrial DNA by associating with mitochondrial transcription factor A 
(TFAM) and promoting TFAM-mediated transcription (Kuroda et al., 2006). Accordingly, 
the event is attenuated by parkin expression silencing with siRNA. However, an important 
caveat is that parkin-induced mitochondrial biogenesis only occurs in proliferating but not 
differentiated cells (Kuroda et al., 2006). Hence, its relevance to post-mitotic cells like 
neurons is unclear. From the recent work by Shin and colleagues, we now know that parkin 
can also potentially regulate mitochondrial biogenesis by regulating PGC-1α expression 
indirectly through its ability to down-regulate PARIS (which represses PGC-1α expression) 
(Shin et al., 2011). PGC-1α regulates a variety of genes that play important roles in 
mitochondrial biogenesis. Amongst these PGC-1α-regulated genes is nuclear respiratory 
factor-1 (NRF-1), whose activity contributes to the expression of respiratory subunits and 
mitochondrial transcription factors (Scarpulla, 2008). Notably, both PGC-1α and NRF-1 
expression are reduced in the SN of PD brains (Shin et al., 2011), suggesting that impaired 
renewal of neuronal mitochondria may contribute to DA neurodegeneration in parkin-
related cases. Based on these results, it is also logical to speculate that parkin might assist in 
the replenishment of exited mitochondria following extensive mitophagy. Thus, parkin 
appears to be involved in the entire spectrum of mitochondrial dynamics, i.e. from 
biogenesis to clearance. 
2.4 Parkin is a potent neuroprotectant   
Given the critical role of parkin in regulating protein and mitochondrial homeostasis, it is 
perhaps unsurprising to note that parkin is capable of protecting neurons against a wide 
variety of insults, including those mediated by α-synuclein or mutant LRRK2, as well as 
those generated by dopamine quinones, neurotoxins or metallic ions (Feany and Pallanck, 
2003; Winklhofer, 2007). Yet, it remains rather amazing at the same time to note that a single 
ubiquitin ligase could do all that. Moreover, several studies have also demonstrated that 
parkin can afford protection against neurotoxicity elicited by agents that are not directly 
related to PD. For example, parkin is apparently capable of mitigating cytotoxicity induced 
by β-amyloid or by expanded polyglutamine-containing proteins through facilitating their 
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elimination from the cell (Rosen et al., 2010; Tsai et al., 2003). While the removal of aberrant 
proteins or damaged mitochondria from cells undergoing various forms of stress may be 
common denominators underlying the broad neuroprotective capacity of parkin, recent 
studies also implicated a more direct role for parkin in neuroprotective signalling. Indeed, 
parkin-mediated ubiquitination is important for the activation of major cellular pro-survival 
pathways such as the NF-κB pathway (Henn et al., 2007). Henn and colleagues 
demonstrated in cells treated with kainate (an excitotoxin) or rotenone (a mitochondrial 
complex I inhibitor) that parkin-mediated protection against cell death is dependent on NF-
κB activity (Henn et al., 2007). Interestingly, the authors further showed that the activation 
of NF-kB pathway by parkin is associated with its K63 polyubiquitination activity (Henn et 
al., 2007). Notably, several studies have also reported the ability of parkin to suppress stress-
related mitogen-activated protein kinase (MAPK) signalling (e.g. JNK and p38) (Cha et al., 
2005; Ren et al., 2009), although the effect may be an indirect consequence of reduced 
oxidative stress level in the presence of parkin. 
Besides its catalytic role, parkin can also promote neuroprotection in an ubiquitination-
independent manner. For example, Ren and colleagues have demonstrated that parkin does 
not require its ligase activity to stabilize microtubules and that this activity-independent 
function of parkin is important in the protection of DA neurons against microtubule-
deploymerizing toxins (Ren et al., 2009). In a separate development, a provocative report 
suggested that parkin possesses ubiquitination-independent transcriptional activity, which 
in this case acts as a repressor of the tumor suppressor p53 expression. The repression of p53 
expression by parkin ultimately leads to decreased Bax transcription, caspase 3 activity and 
apoptosis (da Costa et al., 2009). Although the subject of parkin’s nuclear residency is 
currently still controversial, it is noteworthy that parkin localization to the nucleus has been 
independently observed by at least one other group (Kao, 2009a). Kao showed that parkin 
translocates to the nucleus following DNA damage (Kao, 2009a), apparently to assist in 
DNA repair (Kao, 2009b). Since parkin lacks a defined nucleus localization signal, precisely 
how the translocation of parkin occurs under different conditions remains to be elucidated. 
Notwithstanding the gaps in our current knowledge regarding the mechanisms underlying 
parkin-mediated protection, it is clear that parkin functions as a broad-spectrum 
neuroprotectant. Conceivably, parkin gene delivery could offer a novel avenue of PD 
therapy. Indeed, virus-mediated delivery of parkin has been shown to prevent DA 
neurodegeneration in rats either overexpressing α-synuclein (Lo Bianco et al., 2004; Yamada 
et al., 2005) or treated with parkinsonian neurotoxins (Paterna et al., 2007), or in a non-
human primate model of α-synuclein overexpression (Yasuda et al., 2007). Another way to 
harness parkin’s protective function is to look for molecules that can functionally 
compensate for loss of parkin function. Notably, Tain and colleagues have recently 
demonstrated that pharmacological activation of 4E-BP (Thor) expression in parkin null flies 
by rapamycin can suppress all their pathologies (Tain et al., 2009), suggesting that 
rapamycin can somehow mimic parkin neuroprotection in the absence of the ubiquitin 
ligase.  
2.5 Mammalian models of parkin-related parkinsonism 
Given that parkin-related parkinsonism transmits in a largely recessive fashion and that 
parkin function is clearly important for neuronal homeostasis, one would intuitively be 
optimistic about generating a representative model of parkin-related parkinsonism through 
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the ablation of endogenous parkin in animals. Although Drosophila parkin null mutants do 
exhibit prominent parkinsonian features (including DA neuronal loss and locomotive 
defects) that progress with age, germline-derived parkin knockout mice generally fail to 
exhibit robust signs of parkinsonism (Dawson et al., 2010; Perez and Palmiter, 2005).  On the 
other hand, biochemical and proteomic analyses of brain samples prepared from these mice 
revealed deficits in dopamine handling, reduced mitochondrial respiration and antioxidant 
capacity, as well as increased ROS-mediated damage, all of which are consistent with the 
implicated cellular roles of parkin (Goldberg et al., 2003; Itier et al., 2003; Palacino et al., 
2004). Conceivably, other proteins like PINK1 and DJ-1 that have overlapping functions 
with parkin may help to mitigate the overt manifestation of phenotypes in parkin null mice. 
However, it is noteworthy that even parkin/PINK1/DJ-1 triple knockout mice do not exhibit 
any evidence of nigral degeneration or dramatic pathology, at as late as 24 months of age 
(Kitada et al., 2009).  
Why conventional parkin knockout mice (and for that matter the majority of genetic mouse 
models of PD generated via traditional means) consistently failed to produce significant 
nigral cell loss and associated phenotypes remains a puzzle, although the controlled 
environment that these animals frequently lived in may deny them the entry of unknown 
disease-promoting factor(s) that might be present in the environment at large. Notably, even 
individuals with overt parkin mutations typically require a few decades for the disease to 
surface, suggesting pathogenic interaction between genetic mutations and age-associated or 
other factors. Alternatively, compensatory mechanisms that kicked in during development 
may influence the onset of disease symptoms in humans and mouse alike. Supporting this, 
virus-mediated delivery of PD-linked genes into the SN of adult rodents via stereotactic 
injections, which effectively bypass developmental compensation, usually results in marked 
DA neurodegeneration (Ulusoy et al., 2008). As mentioned earlier, such an approach was 
taken by Shin and colleagues, who generated a conditional parkin knockout mice by which 
exon 7 of the parkin gene flanked by loxP sites was removed from the SN of adult mice 
following stereotactic injection of a Cre recombinase-containing lentiviral vector (Shin et al., 
2011). This elegant approach leads to a dramatic loss of parkin expression from the ventral 
midbrain of injected mice that is accompanied by an age-dependent loss of DA neurons, 
although the motor parameters of these mice were not reported. Thus, loss of parkin 
function in adult mice does promote DA neuronal loss, albeit in a conditional-dependent 
manner. At the same time, the study also provided indirect evidence supporting that the 
pathogenicity arising from the loss of parkin function can be developmentally compensated 
(at least in mice). Such compensatory mechanisms may conceivably operate in humans and 
may account for the age-dependency and the heterogeneity of age of onset of PD. At the 
least, we now have a model of parkin-linked recessive parkinsonism that exhibits 
substantial and progressive nigral cell loss. 
A different approach was taken by Lu and colleagues in modelling parkin dysfunction in 
mice. In view of the possibility that single parkin mutations may also contribute to the 
disease, the group developed a BAC (bacterial artificial chromosome) transgenic mouse 
model expressing a C-terminal truncated human mutant parkin (Parkin-Q311X) in DA 
neurons under the direction of a dopamine transporter promoter (Lu et al., 2009). 
Expression of Parkin-Q311X, an aggregation-prone mutant, in mice produces age-dependent 
loss of SN DA neurons that is accompanied by progressive hypokinetic motor deficits. These 
results suggest that certain parkin mutants may exert direct neurotoxicity and support the 
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role of heterozygous parkin mutations in disease pathogenesis. Notably, previous studies 
conducted in the Drosophila by the same group as well as by our group also arrived at the 
same suggestion (Sang et al., 2007; Wang et al., 2007). Indeed, transgenic flies expressing 
human parkin mutants such as R275W and Q311X display age-dependent, selective loss of 
DA neurons that is accompanied by progressive locomotion deficits (Sang et al., 2007; Wang 
et al., 2007). 
2.6 Relevance of parkin to sporadic PD   
That parkin mutations transmit in a recessive manner would suggest that the loss of parkin 
function predisposes DA neurons to degeneration. An important corollary to this is that any 
post-translational event that promotes the loss of parkin function could potentially mimic 
the effects brought about by overt mutations and be just as detrimental. Further, in view of 
the suggested contribution of parkin haploinsufficiency to disease risk, it is reasonable to 
assume that the down-regulation of normal parkin function mediated by such events need 
not result in the total abolition of its enzymatic activity to elicit a pathogenic effect.  
We and others have found that a wide variety of PD-linked stressors, including those that 
produce oxidative and nitrosative stress, induce parkin solubility alterations and thereby its 
aggregation in a manner analogous to that brought about by several of its missense 
mutations (LaVoie et al., 2005; Wang et al., 2005; Winklhofer et al., 2003). Remarkably, 
dopamine also modifies parkin in a similar fashion (LaVoie et al., 2005; Wang et al., 2005). 
Furthermore, parkin appears to be uniquely susceptible to dopamine-induced modifications 
compared to several other related E3 members such as HHARI, Cbl and CHIP (LaVoie et al., 
2007; LaVoie et al., 2005; Wong et al., 2007). Accordingly, detergent-insoluble parkin, but not 
HHARI, Cbl and CHIP, accumulates in the PD brain (LaVoie et al., 2005; Wang et al., 2005; 
Wong et al., 2007). As optimal level of soluble parkin is important for neuronal survival, the 
immobilization of the parkin within aggregates would not only deprive the protein of its 
function but also effectively reduce the pool of functional parkin available to the cell. Like 
haploinsufficiency, the biochemical depletion of soluble parkin levels is expected to increase 
the vulnerability of susceptible neurons to degeneration. Interestingly, normal parkin in the 
brain also becomes progressively more detergent-insoluble with aging (Pawlyk et al., 2003), 
which may provide an explanation to why age represents a risk factor for PD.  
Besides stress-induced modifications, parkin phosphorylation is another post-translational 
modification that is linked to its inactivation. Notably, serine phosphorylation of parkin by 
casein kinase 1 (CK1) or cyclin-dependent kinase 5 (Cdk5) reportedly down-regulates its 
activity (Avraham et al., 2007; Yamamoto et al., 2005), and compound phosphorylation of 
parkin by both kinases further leads to its aggregation (Rubio de la Torre et al., 2009). While 
the physiological role of parkin phosphorylation remains unclear, it is conceivable that 
aberrant CK1 or Cdk5 activity can promote loss of parkin function and play a role in 
sporadic PD pathogenesis. Supporting this, parkin phosphorylation is elevated in distinct 
regions of sporadic PD brains and correlates with increased levels of p25, the activator of 
CDK5 (Rubio de la Torre et al., 2009). More recently, Ko and colleagues have demonstrated 
that tyrosine phosphorylation of parkin at residue 143 (Y143) by the src family kinase 
member, c-Abl, similarly inactivates its enzyme activity and compromises its protective 
function both in vitro and in vivo (Ko et al., 2010). They further showed that parkin is 
tyrosine-phosphorylated at Y143 in human post-mortem PD brains and that this 
modification of parkin is accompanied by the accumulation of parkin substrates such as 
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AIMP2. Together, the results by Ko and colleagues suggest a pathophysiologic regulation of 
parkin by c-Abl in sporadic PD (Ko et al., 2010). 
Other than the above-mentioned post-translational modifications, a number of parkin 
interactors have also been demonstrated to be capable of inactivating its E3 ligase activity. For 
example, the bcl-2-associated athanogene 5 (BAG5) associates with and inhibits parkin activity 
(Kalia et al., 2004). Further, BAG5 promotes the sequestration of parkin within protein 
aggregates and compromises its neuroprotective function. Accordingly, targeted expression of 
BAG5 in the SNpc of mice enhances DA neurodegeneration following axotomy-induced DA 
neuronal injury or MPTP administration (Kalia et al., 2004). Although the authors suggested 
that BAG5 may serve as a useful therapeutic target for PD, the mechanism by which BAG5 
inhibits parkin E3 activity remains unclear to this date. It is also curious why DA neuronal 
injury would induce BAG5 expression, an event that inhibits rather than stimulates the 
neuroprotective activity of parkin, which invariably will worsen the condition. Notably, 
besides BAG5, several other parkin interactors have also been identified as modulators of its 
catalytic activity. These include 14-3-3η, a chaperone-like protein, and Nrdp1, a RING-finger 
containing ubiquitin ligase (Sato et al., 2006; Zhong et al., 2005). Whereas 14-3-3η interacts with 
and reduces parkin activity directly (Sato et al., 2006), Nrdp1 promotes parkin degradation 
and depletes the availability of parkin to the cell (Zhong et al., 2005). Both events if 
unregulated would obviously be detrimental to parkin’s protective function. 
Taken together, it is apparent that loss of parkin function is not limited to those induced by 
disease-causing mutations, but also includes several biochemical and protein-protein 
modifications that can either alter the catalytic function of the E3 ligase directly, or indirectly 
through promoting its aggregation or degradation. Collectively, these mutation-
independent modifications that inactivate parkin activity provide a mechanism for parkin 
dysfunction that is relevant to the pathogenesis of sporadic PD.  
3. Conclusion 
It is evident from the above discussion that parkin plays a key role in maintaining DA 
neuronal homeostasis and that its dysfunction is relevant to not just familial parkinsonism 
but also to sporadic PD. Parkin thus represents a neuroprotective PD-linked gene whose 
function can be and arguably should be exploited. Accordingly, a better understanding of 
parkin-mediated neuroprotective pathways would offer opportunities to uncover molecular 
targets that may be of therapeutic value to both familial and sporadic PD. The Drosophila 
model, with its powerful genetics as well as its amenability to drug screening, will be 
particularly useful here. Alternatively, given that the loss of parkin function can apparently 
be developmentally compensated (at least in mice), the identification and validation of 
components of the compensatory network will represent another approach to elucidate 
rational therapeutic strategies. Indeed, from a therapeutics point of view, it may be equally 
(if not more) beneficial to understand how parkin-related cases as well as PD in general are 
kept in check for decades before disease onset than to map the precise pathogenic events 
that occur after disease onset.  
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